Andre H. Goy, MD

Panelists discuss how the preliminary results from the iMMagine-1 trial of anitocabtagene autoleucel in relapsed/refractory multiple myeloma (R/R MM) highlight promising efficacy in triple-class and penta-class refractory patients, potentially reshaping treatment strategies and challenging existing paradigms in managing heavily pretreated myeloma.

Panelists discuss how real-world comparative analyses reveal nuanced differences in the efficacy and safety profiles of ciltacabtagene autoleucel and idecabtagene vicleucel among patients with relapsed/refractory multiple myeloma (R/R MM), highlighting the critical importance of translating clinical trial data into practical treatment strategies.

Panelists discuss how real-world analyses of chimeric antigen receptor (CAR) T-cell therapies in relapsed/refractory multiple myeloma (R/R MM), as presented in abstract #2408 by Amoozgar et al at ASH 2024, provide insights into the comparative efficacy and safety of ciltacabtagene autoleucel and idecabtagene vicleucel, highlighting differences between real-world outcomes and clinical trial results.

Panelists discuss how key data from ASH 2024 impact current approaches to treating hematologic malignancies, with a focus on multiple myeloma, lymphoma, and leukemia.

Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology.

Andre H. Goy, MD, discusses key findings from an assessment of durable responses in the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Andre H. Goy, MD, discusses the clinical implications of treating indolent mantle cell lymphoma.

Andre H. Goy, MD, discusses clinical trial vs real-world treatments in patients with mantle cell lymphoma.

Maher Albitar, MD, and Andre H. Goy, MD, discuss case studies in diffuse large B-cell lymphoma.

Maher Albitar, MD, and Andre H. Goy, MD, discuss the importance of testing for molecular abnormalities in acute myeloid leukemia.

Maher Albitar, MD, and Andre H. Goy, MD, share insights regarding molecular complexities in mantle cell lymphoma.

Maher Albitar, MD, and Andre H. Goy, MD, discuss practical aspects of next-generation sequencing.

Lori A. Leslie, MD, and Andre H. Goy, MD, share strategies for when CAR T-cell therapy is not an option.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss approaches to CAR T-cell therapy.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss optimal strategies for CAR T-cell–related adverse effects.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss retreatment with CAR T-cell therapy.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss next steps with CAR T-cell therapy.

Andre H. Goy, MD, discusses the clinical data reported with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma and real-world findings with brexucabtagene autoleucel in mantle cell lymphoma.

Andre Goy, MD, discusses the clinical implications of CAR T-cell therapy in mantle cell lymphoma.

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.